Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $401.8-$402.8 million and Precision Oncology revenue of $142.9-$143.9 million
Expected total 2022 revenue, excluding COVID-19 testing, increased 25% compared to 2021, with Screening revenue of $1,423.0-$1,424.0 million and Precision Oncology revenue of $601.0-$602.0 million
Adjusted EBITDA profitability now expected for the fourth quarter 2022 and full year 2023, ahead of previous target of third quarter 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.